Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Boston Scientific (BSX) is outperforming its medical sector peers, with a year-to-date return of 15.1% compared to the sector's average loss of 4.4%; this outperformance is supported by a Zacks Rank of #2 (Buy) and a 2.3% increase in the consensus estimate for full-year earnings over the past 90 days. Dare Bioscience (DARE) is another medical stock showing relative strength, with a 4.5% year-to-date return and an 8.2% increase in its current year EPS estimate over the last three months, earning it a Zacks Rank #1 (Strong Buy).

Analysis

Boston Scientific (BSX) has demonstrated significant market outperformance year-to-date, delivering a return of approximately 15.1%, starkly contrasting with the Medical sector's average loss of 4.4%. This robust performance is underpinned by a Zacks Rank of #2 (Buy), indicating a positive outlook, which is further supported by a 2.3% upward revision in the Zacks Consensus Estimate for BSX's full-year earnings over the past 90 days, signaling strengthening analyst sentiment and an improving earnings trajectory. Within its specific Medical - Products industry, which has gained an average of 5.8% year-to-date, BSX is also a notable outperformer. Similarly, Dare Bioscience, Inc. (DARE) has returned 4.5% year-to-date, outperforming the broader Medical sector. DARE holds a Zacks Rank #1 (Strong Buy), and its consensus EPS estimate for the current year has increased by 8.2% over the past three months. However, DARE's Medical - Biomedical and Genetics industry has seen a decline of 3.9% since the beginning of the year. Both companies are highlighted as potentially maintaining their solid performance amidst varying sector and industry trends.

Key Decisions for Investors

• Investors should consider Boston Scientific's strong relative strength, evidenced by its 15.1% year-to-date return against a declining Medical sector, and its positive earnings estimate revisions as indicators of potential continued upside.
• Dare Bioscience, with its 'Strong Buy' rating and significant positive EPS estimate revisions, warrants attention as another outperformer, though its industry's negative trend should be monitored.
• Monitor both BSX and DARE for sustained earnings momentum and any shifts in analyst sentiment, as these factors are key drivers of their current positive outlooks highlighted in the report.